Clinical Trials Sponsored by AztraZeneca

Total 4307 results

AstraZeneca

Completed

Effect of Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Tiotropium: The HELIOS Study (BY217/M2-128) (HELIOS)

Chronic Obstructive Pulmonary Disease

France, Germany, Italy, Spain, United Kingdom, Austria, Hungary
AstraZeneca

Completed

Effect of Ciclesonide on Quality of Life in Patients With Moderate Persistent Asthma (21 to 65 y) (BY9010/AR-101)

Asthma

Argentina
AstraZeneca

Completed

Pharmacodynamic/Pharmacokinetic Interactions Between Oral Roflumilast and Inhaled Formoterol

Healthy

Germany
AstraZeneca

Completed

Efficacy and Safety of Oral Roflumilast Taken Once Daily in Patients Older Than 40 Years With Chronic Obstructive Pulmonary Disease (BY217/M2-119)

COPD

Korea, Republic of, Malaysia, Taiwan, Hong Kong, Philippines
AstraZeneca

Completed

Safety and Effectiveness of Ciclesonide Nasal Spray in Children (6 to 11 Years) With Perennial Allergic Rhinitis (BY9010/M1-403)

Allergic Rhinitis | Perennial Allergic Rhinitis | Hay Fever

United States, Canada
AstraZeneca

Completed

Study Using the Environmental Exposure Chamber (EEC) to Assess the Onset of Action of Ciclesonide, Applied as a Nasal Spray in Treatment of Seasonal Allergic Rhinitis (BY9010/M1-406)

Rhinitis, Allergic, Seasonal | Hay Fever

Canada
AstraZeneca

Completed

To Assess the Safety and Efficacy of Ciclesonide, Applied as a Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (BY9010/M1-401)

Rhinitis, Allergic, Seasonal | Hay Fever

United States
AstraZeneca

Completed

OPUS Study: Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (BY217/M2-111)

Chronic Obstructive Pulmonary Disease | COPD

United States, France, Poland, South Africa, Canada, Germany
AstraZeneca

Completed

Investigation of Potential Additive Inhibitory Effects on HPA-Axis of Ciclesonide Nasal Spray When Administered Concomitantly With Orally Inhaled Beclomethasone Dipropionate (HFA-BDP) in Patients With Perennial Allergic Rhinitis (PAR) (BY9010/M1-408)

Rhinitis, Allergic, Perennial

United States
AstraZeneca

Completed

Efficacy of Ciclesonide vs Fixed Combination of Fluticasone Propionate/Salmeterol vs Placebo in Patients With Mild Persistent Asthma (12 to 75 y) (BY9010/M1-132)

Asthma

Hungary, South Africa, Poland, Spain, Canada, Australia, Czech Republic
AstraZeneca

Completed

Investigation of the Efficacy and Safety of Concomitant Administration of Ciclesonide Nasal Spray and Azelastine Nasal Spray in Patients (18 Years or Older) With Perennial Allergic Rhinitis (PAR) Not Adequately Controlled on an Intranasal Corticosteroid or Antihistamine Monotherapy (BY9010/M1-490)

Rhinitis, Allergic, Perennial

United States
AstraZeneca

Completed

Clinical Trial to Assess Rate of Onset of Bronchodilator Action in Severe Stable Chronic Obstructive Pulmonary Disease (COPD) Patients

Chronic Obstructive Pulmonary Disease (COPD)

United Kingdom
AstraZeneca

Completed

Efficacy and Safety of Olaparib in Pretreated Patients With Measurable Colorectal Cancer, Stratified by Microsatellite Instability (MSI) Status

Colorectal Cancer

United States
AstraZeneca

Completed

Epidemiology of Chronic Bronchitis in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease | Chronic Bronchitis
AstraZeneca

Completed

Quality of Life in Daxas-treated Patients Older Than 18 Years With Severe COPD (DINO)

Severe COPD

Germany
AstraZeneca

Completed

The HERO-study: Effects of Roflumilast in Patients With COPD (Chronic Obstructive Pulmonary Disease) (BY217/M2-121)

Chronic Obstructive Pulmonary Disease, COPD

France, Poland, South Africa, Spain, United States, Canada, United Kingdom
AstraZeneca

Completed

Efficacy and Safety of Roflumilast in Patients With Asthma (BY217/M2-012)

Asthma

United States, Argentina, Colombia, Mexico, Peru
AstraZeneca

Completed

Investigate the Safety and Tolerability of AZD6244 Monotherapy or + Docetaxel in Japanese Patients With Advanced Solid Malignancies or Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer | Advanced Solid Malignancies | Neoplasms, | Metastatic Cancer,

Japan
AstraZeneca

Completed

To Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of Olaparib, and the Effect of Olaparib on QT Interval Following Oral Dosing of a Tablet Formulation to Patients With Advanced Solid Tumours

Solid Tumours

Belgium, Denmark, United Kingdom, Netherlands
AstraZeneca

Completed

Evaluation of Symptoms Improvement in NSCLC Patients With First-Line Therapy of EGFR Tyrosine Kinase Inhibitor

Non-Small-Cell Lung Cancer

Taiwan
AstraZeneca

Completed

Acid Suppressing Drug Seizure Epidemiology Study

Seizure

Spain
AstraZeneca

Completed

Study to Evaluate the 2-Way Interaction Between Multiple Doses of Epanova™ and a Single Dose of Rosuvastatin (Crestor®) (ECLIPSEIII)

Hypertriglyceridemia

United States
AstraZeneca

Completed

AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer.

Advanced Breast Cancer

United States, Australia, Brazil
AstraZeneca

Completed

Descriptive Pharmacoepidemiological Study of Patients Treated With Iressa (EPIDAURE)

Lung Cancer

France
AstraZeneca

Completed

Drug-Drug Interaction Study With AZD9291 and Omeprazole in Healthy Volunteers

Healthy Volunteer

United States
AstraZeneca

Completed

Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes

Type 2 Diabetes

United States, Puerto Rico, Mexico, Russian Federation, Romania, Poland, Czech Republic, United Kingdom
AstraZeneca

Completed

Perception of Symptom Variability in COPD

Chronic Obstructive Pulmonary Disease

China
AstraZeneca

Terminated

A Placebo Controlled Study Comparing AZD1775+ Docetaxel Versus Placebo+Docetaxel to Treat Lung Cancer

Previously Treated Non Small Cell Lung Cancer

United States
AstraZeneca

Terminated

Ticagrelor vs Clopidogrel in Non-ST Elevation Acute Coronary Syndrome Patients Undergoing PCI With Bivalirudin. (NSTE-ACS)

Non-ST Elevation Acute Coronary Syndrome

United States
AstraZeneca

Completed

A Study to Investigate the Effect of Food on Pharmacokinetics of Total EPA and Total DHA of AZD0585 in Healthy Male Japanese Subjects

Healthy

Japan
AstraZeneca

Withdrawn

Effectiveness of Statins on Lipid Goal Attainment and Lipid Parameters in PCI Patients

PCI Patients
AstraZeneca

Completed

CEntralized Pan-Russian Survey of tHE Undertreatment of hypercholeSterolemia II (CEPHEUS II) (CEPHEUSII)

Dyslipidaemia

Russian Federation
AstraZeneca

Completed

Bioequivalence Study Coadministered to Healthy Subjects in the Fasted State

Type 2 Diabetes Mellitus
AstraZeneca

Completed

Open Label Phase 1 Study in Japan for Patient With Advanced Solid Malignancies

Advanced Solid Tumor | Advanced Solid Malignancy

Japan
AstraZeneca

Completed

Comparison of AZD6244 in Combination With Dacarbazine Versus (vs) Dacarbazine Alone in BRAF Mutation Positive Melanoma Patients

Melanoma

Sweden, United States, Brazil, Czech Republic, France, Spain, United Kingdom, Germany, Norway, Hungary, Netherlands, Switzerland
AstraZeneca

Completed

Study of Aclidinium Bromide/Formoterol Fumarate Compared With Salmeterol/Fluticasone Propionate in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

Austria, Bulgaria, Canada, Czech Republic, France, Germany, Hungary, Italy, Lithuania, Netherlands, Poland, South Africa, Spain, United Kingdom
AstraZeneca

Completed

A Phase II Study to Evaluate the Efficacy, Safety and Tolerability of AZD5069 in Patients With Uncontrolled Persistent Asthma. (NIMBUS)

Asthma

Bulgaria, Czech Republic, Mexico, Poland, Russian Federation, South Africa, United Kingdom, Germany, Romania, Ukraine, Canada, Hungary, Slovakia
AstraZeneca

Completed

The Tolerability and Effects of AZD8848 in Allergic Asthma Subjects Challenged With Inhaled Allergen

Allergic Asthma

United Kingdom
AstraZeneca

Completed

Distribution of Neutrophils in Bronchial Mucosal Tissue in Asthma Patients Before and After 4 Weeks Treatment With AZD 5069

Asthma

Germany
AstraZeneca

Completed

Safety and Efficacy of AZD4547 in Combination With Fulvestrant vs. Fulvestrant Alone in ER+ Breast Cancer Patients (GLOW)

FGFR Inhibition, Pharmacokinetics, Biomarkers | ER+ Breast Cancer

Czech Republic, Italy, United Kingdom, Hungary, Germany, Romania, Belgium, France
AstraZeneca

Completed

A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Hormone Resistant Prostate Cancer With Bone Metastases (ENTHUSE M1)

Prostate Cancer

Sweden, United States, Brazil, Czech Republic, France, Russian Federation, United Kingdom, Germany, China, Hungary, Poland, Finland, Netherlands, Mexico, Hong Kong, Australia, Belgium, Canada, Denmark, Portugal, South Africa, Korea... and more
AstraZeneca

Completed

Explore the Performance of IntelliCap.

Pharmacokinetic Profile | Plasma Concentration

United Kingdom
AstraZeneca

Completed

Phase I/II AZD8931/Paclitaxel in Treatment of Advanced Solid Tumours (Phase I) and Advanced Breast Cancer (Phase II) (THYME)

Neoplasms | Breast Cancer | Breast Neoplasms

Brazil, Bulgaria, Czech Republic, Peru, Spain, United Kingdom, Sweden, Hungary, Belgium, Canada, Italy, France, Panama, Switzerland
AstraZeneca

Completed

CARIATIDE (Compliance of ARomatase Inhibitors AssessmenT In Daily Practice Through Educational Approach) (CARIATIDE)

Breast Cancer

Croatia, Sweden, Czech Republic, France, Italy, Peru, Turkey, United Kingdom, Romania, Finland, Australia, Austria, Belgium, Switzerland, Greece, Colombia, Chile, Venezuela
AstraZeneca

Completed

LINE: Treatment Patterns in postmenopausaL Women With Hormone Receptor Positive Breast Cancer (LINE)

Local Advanced or Metastatic Postmenopausal Breast Cancer

Russian Federation
AstraZeneca

Completed

Ad Hoc Percutaneous Coronary Intervention Study in Acute Coronary Syndrome Patients

Acute Coronary Syndrome

United States
AstraZeneca

Completed

Canadian Ticagrelor Survey

Acute Coronary Syndrome

Canada
AstraZeneca

Completed

Real Life Effectiveness in Patients With Not Optimally Controlled Asthma

Asthma

Taiwan
AstraZeneca

Completed

To Assess the Effects of Single Oral Dose of Selumetinib [AZD6244; ARRY-142886] [Hyd-Sulfate]), on QTc Interval in Healthy Male Volunteers

Solid Tumours

United States
AstraZeneca

Completed

Global Phase1 Study to Assess the Safety and Tolerability of AZD1208 in Advanced Solid Tumors and Malignant Lymphoma

Advanced Solid Malignancies | Malignant Lymphoma

United Kingdom, Japan

3

Subscribe